Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Raises $43M in Series F Round

NEW YORK – Epic Sciences announced on Wednesday that it raised $43 million in a Series F financing round led by Arsenal Capital Partners.

Other investors included Blue Ox Healthcare Partners, Deerfield Management, and Labcorp.

Epic plans to use the funds raised to further develop its DefineMBC multiomic metastatic breast cancer liquid biopsy assay and to expand in areas such as single-cell sequencing and data analytics infrastructure.

DefineMBC is a lab-developed test that combines analyses of circulating tumor cells, single-cell whole-genome sequencing, and cell-free DNA sequencing into a single assay. It is used to comprehensively profile metastatic breast cancer when a tissue biopsy is unavailable.

Epic also appointed James Rothman, chair of Arsenal's Healthcare Advisory Board, and Richard Eglen, a senior adviser to Arsenal, to its board of directors.

"We are continuing to innovate testing for both the research and clinical markets," Lloyd Sanders, Epic's president and CEO, said in a statement. "Our biopharma partners are driving our presence into drug development efforts and an increasing number of clinical trials, while we continue to see growing excitement from practicing clinical oncologists for DefineMBC and future tests."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.